Dr. John Cush RheumNow
7 years 4 months ago
RheumNow Podcast from EULAR19 is up! EULAR 2019 Streamin' (6.14.19). You can view it here>> https://t.co/fTdH4kuCJX or listen on iTunes or SoundCloud >> https://t.co/TGxUixKoIj
A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.
Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?
Dr. John Cush RheumNow
7 years 4 months ago
RheumNow expanded twitter coverage of the #EULAR2019 annual meeting is sponsored by Horizon Pharma. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow
7 years 4 months ago
#EULAR2019 commentary on RheumNow's meeting coverage site: https://t.co/5zpSSNXARC - hope you check it out. It features tweets, video interviews, articles and more. Our final meeting wrap up hits tomorrow. Hope everyone had safe travels home.
Janet Pope Janetbirdope
7 years 4 months ago
Eular highlights. Unanswered questions. Need RCTs in severe RA with targeted DMARD + biological? Should we cycle JAKs - need RCT. ?change target in RA to reflect real disease activity- inflammation and consider PROs separately #EULAR2019 @RheumNow
Janet Pope Janetbirdope
7 years 4 months ago
Eular highlights. Need to know if order of Rx of advanced therapies makes a long term difference in RA and PsA. ?better effectiveness or retention with one strategy vs another. ?too much drug cycling #EULAR2019 @RheumNow
Emilio Martin Mola emartinmola
7 years 4 months ago
Bad news. Chikungunya has arrived to Spain. The mosquito bites happened last May in Alicante.
Tres turistas islandeses en Alicante, primeros infectados de chikungunya en España https://t.co/v89dEVyFHr vía @el_pais
Md Yuzaiful Md Yusof Yuz6Yusof
7 years 4 months ago
Interesting talks from @GeorgeTsokos. Response to Ustekinumab in #lupus trial was associated with reduction in IFN-gamma (IFN-II) but not IL17 (A & F), 22 or IFN-I signature (IFN-alpha) #EULAR2019 https://t.co/xZP4qjSUnH
Juan Ovalles, MD, PhD DrJuanOvalles
7 years 4 months ago
Major Unanswered Question: according to EULAR Recommendations a regular follow-up and monitoring of disease activity in patients with large vessels vasculitis is recommended
👉🏻But how often❓
👉🏻Is imaging useful at all❓
👉🏻How to screen for vessel stenosis & aneurysms❓#EULAR2019 https://t.co/xFvq1qfIGN
Janet Pope Janetbirdope
7 years 4 months ago
Fibromyalgia Rx in EULAR guidelines includes amitryptylline which won the vote and duloxetine and neurontin or gabapentin which others chose. New thinking is to decide on Rx by type of pain. Don't forget exercise, sleep hygiene, CBT #EULAR2019 @RheumNow https://t.co/XEKG6WBU1i
Janet Pope Janetbirdope
7 years 4 months ago
Pts with RA have shame and guilt which correlates with demographics and disease activity. Something to think about, acknowledge and give proper help. FRI0030 #EULAR2019 @RheumNow
CreakyJoints.org CreakyJoints
7 years 4 months ago
More in #gout news from #EULAR2019: men on uric acid-lowering therapy (and only 1/3 of people in this study were) were less likely to visit the #ER than those who weren’t
David Liew drdavidliew
7 years 4 months ago
Low dose steroids in RA are benign? I speak to @dr_rachelblack about cataract and glaucoma risk from steroids for @RheumNow (data from SAT0592 at #EULAR2019) https://t.co/3Qo4dZdTNK https://t.co/1kLQ2VwSD3
Lupus Foundation of America · #LupusAwarenessMonth LupusOrg
7 years 4 months ago
BIIB059 is a monoclonal antibody that blocks BDCA2, which inhibits the production of inflammatory mediators in SLE. A Phase 1 trial showed drug to be safe& tolerable. It continues being investigated in SLE& cutaneous #lupus. #EULAR2019 #InsideLupusResearch https://t.co/bbcV3W57DD
